Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
323.15B
Market cap323.15B
Price-Earnings ratio
29.65
Price-Earnings ratio29.65
Dividend yield
1.97%
Dividend yield1.97%
Average volume
2.30M
Average volume2.30M
High today
$162.19
High today$162.19
Low today
$159.96
Low today$159.96
Open price
$160.68
Open price$160.68
Volume
1.07M
Volume1.07M
52 Week high
$170.46
52 Week high$170.46
52 Week low
$121.57
52 Week low$121.57

NVS News

Zacks 1d
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie

Chicago, IL – October 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the l...

The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
TipRanks 2d
Novartis Earnings Call: Core Strength Amid Pipeline Tests

Novartis AG ((NVS)) has held its Q3 earnings call. Read on for the main highlights of the call. Novartis’ latest earnings call struck an upbeat tone, with mana...

Investing.com 2d
Novartis earnings analysis: questions answered and next catalysts - Investing.com

...

Novartis earnings analysis: questions answered and next catalysts - Investing.com

Analyst ratings

50%

of 8 ratings
Buy
50%
Hold
50%
Sell
0%

More NVS News

Benzinga 2d
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit

Novartis AG (NYSE:NVS) reported mixed third-quarter earnings on Tuesday as the prized Avidity Biosciences deal worth $12 billion cost the company an estimated $...

Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit
Zacks 2d
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss

Swiss pharma giant Novartis AG (NVS Quick QuoteNVS - Free Report) reported third-quarter 2026 core earnings per share (excluding one-time charges) of $2.4...

NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
Investor's Business Daily 2d
Novartis Hikes Income Forecast, But There Were Caveats Within Its Report

Technology Novartis Hikes Income Forecast, But There Were Caveats Within Its Report Licensing Novartis (NVS) stock edged higher early Tuesday after the pharma g...

Novartis Hikes Income Forecast, But There Were Caveats Within Its Report
Zacks 2d
The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP

Chicago, IL – October 27, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the l...

The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP
The Wall Street Journal 2d
Novartis Raises Guidance Despite Trial Setbacks Hitting Profit

Novartis said its net profit result was hit by a $1.9 billion write-down for neuromuscular drug candidate, del-desiran. fabrice coffrini / Agence France-Presse...

Novartis Raises Guidance Despite Trial Setbacks Hitting Profit
TipRanks 6d
Novartis says remibrutinib showed comprehensive disease control in Phase 3 trial

Novartis (NVS) presented positive results from the pivotal Phase 3 REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis, showing that remibrutinib, a...

TipRanks 6d
Novartis announces results from six-year follow up study of Kisqali

Novartis (NVS) announced results from the six-year follow-up analysis of the Phase III NATALEE trial, reporting positive, clinically meaningful overall survival...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.